hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06265064, orgStudyIdInfo id: KhonKaenUniversity, briefTitle: STOP-Bang Score and Factors Predicting Difficult Intubation for Prediction of Difficult Mask Ventilation in Obese Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-07-11, primaryCompletionDateStruct date: 2023-10-31, completionDateStruct date: 2023-10-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Khon Kaen University, class: OTHER, descriptionModule briefSummary: The goal of this prospective observational study is to test combination of STOP-Bang score and factors predicting difficult intubation can improve accuracy of prediction difficult mask ventilation in obese patients that undergoing to elective surgery under general anesthesia.The main question\[s\] it aims to answer are:* Can combination of STOP-Bang score and factors predicting difficult intubation improve accuracy of prediction difficult mask ventilation in obese patients?* Study about complication after endotracheal tube insertion in obese patients that undergoing to elective surgery under general anesthesia.Participants who undergoing to elective surgery under general anesthesia will* Routine preoperative evaluation and ask about STOP bang questions, evaluate neck circumference, Mallampati grade,Thyromental distance (That routine physical examination for anesthetic care pre-operation)* In operation room, patients will be inducted anesthesia by anesthesiologist (step routine for general anesthesia),observe difficult mask ventilation grading before intubate endotracheal tube and complication after endotracheal tube insertion.If there is a comparison group:Researchers will compare obese patients with/without high STOP bang score \>=3 point plus factor predicting difficult intubation (Mallampati grade 3-4, Neck circumference \> 42 cm, Thyromental distance \< 6 cm)to prediction difficult mask ventilation, conditionsModule conditions: Obesity, conditions: OSA, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 278, type: ACTUAL, armsInterventionsModule interventions name: STOP-Bang score >= 3 with factors predicting difficult intubation, outcomesModule primaryOutcomes measure: Difficult mask ventilation, secondaryOutcomes measure: Resipiratory complication, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: KhonKaen University, city: Nai Muang, state: Khonkaen, zip: +66, country: Thailand, geoPoint lat: 15.17901, lon: 100.1282, hasResults: False
protocolSection identificationModule nctId: NCT06265038, orgStudyIdInfo id: SANAT-CAGE-2022, briefTitle: Confirmatory Investigation to Evaluate the Performance and Safety of ReSpace TiCell Cage Implants in TLIF, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2026-02-01, completionDateStruct date: 2026-10-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Sanatmetal Orthopaedic and Traumatologic Equipment Manufacturer Ltd., class: INDUSTRY, descriptionModule briefSummary: The primary objective of this study is to confirm superiority for the efficacy of the ReSpace Ticell Cage implants in Transforaminal Lumbar Interbody Fusion compared to state-of-the-art.The secondary objective of the study is to evaluate further efficacy and safety of the ReSpace Ticell Cage implants in Transforaminal Lumbar Interbody Fusion with the following secondary efficacy and safety objectives:* To evaluate if implantation causes significant reduction in patient's back, hip/buttock, and leg pain.* To evaluate if implantation causes significant increase quality of life of the patients.* To evaluate if using the device can be considered as safe overall., conditionsModule conditions: Degenerative Instability, conditions: Spondylolisthesis, conditions: Post-discectomy Syndrome, conditions: Post-traumatic Instability, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Prospective, single-arm, open-label clinical trial. This clinical investigation addresses to collect data on clinical performance, effectiveness and safety of Sanatmetál's ReSpace TiCell Cage in human subjects following the good clinical practice according to the Medical Device Regulation (MDR) \& EN ISO 14155:2020. The study is conducted in Hungary at National Center for Spinal Disorders., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 99, type: ESTIMATED, armsInterventionsModule interventions name: ReSpace TiCell Cage, outcomesModule primaryOutcomes measure: CT imaging_1 - cumulative fusion rate, primaryOutcomes measure: CT imaging_2 - fusion status, secondaryOutcomes measure: Visual Analog Scale, secondaryOutcomes measure: Oswestry Disability Index (ODI), otherOutcomes measure: AE and ADE, otherOutcomes measure: Complications, otherOutcomes measure: Surgical revisions, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Center for Spinal Disorders, status: RECRUITING, city: Budapest, state: Pest, zip: 1126, country: Hungary, contacts name: Aron Lazary, MD, PhD, role: CONTACT, phone: +36118877900, phoneExt: 5671, email: lazary.aron@gmail.com, geoPoint lat: 47.49801, lon: 19.03991, hasResults: False
protocolSection identificationModule nctId: NCT06265012, orgStudyIdInfo id: PHV01-C-101, briefTitle: Study to Evaluate the Recombinant Vesicular Stomatitis Virus (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects, acronym: PHV01, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-05, primaryCompletionDateStruct date: 2024-04-17, completionDateStruct date: 2024-09-16, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: Public Health Vaccines LLC, class: INDUSTRY, collaborators name: Biomedical Advanced Research and Development Authority, descriptionModule briefSummary: This is a Phase 1 randomized, single-blind, placebo-controlled, ascending dose study to evaluate the safety and immunogenicity of rVSV∆G-MARV-GP \[Angola\] (PHV01, Marburg Virus glycoprotein \[MARV GP\] Vaccine) in healthy adults. PHV01 is a live, attenuated rVSV vaccine expressing the MARV GP. The main questions it aims to answer are:* Which dose of PHV01 is safe to administer to, and well-tolerated by healthy adult subjects?* What is the immunologic response (Marburg-specific Immunoglobulin G (IgG) ELISA antibody and neutralizing antibodies) to each dose level?Participants will receive 1 intramuscular injection of PHV01 or placebo on Day 1 and will be followed for 181 days., conditionsModule conditions: Marburg Virus Disease, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, maskingDescription: Single-blind, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: PHV01, interventions name: Placebo, outcomesModule primaryOutcomes measure: Solicited Adverse Events (AEs), primaryOutcomes measure: Unsolicited AEs, primaryOutcomes measure: Other AEs, primaryOutcomes measure: Immunogenicity, Antibodies (Ab), primaryOutcomes measure: Immunogenicity, Neutralizing antibodies (NEUT), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: CenExel RCA, status: RECRUITING, city: Hollywood, state: Florida, zip: 33024, country: United States, contacts name: Terry Piedra, role: CONTACT, phone: 305-596-3125, email: t.piedra@cenexel.com, contacts name: Amanda Gonzalez, role: CONTACT, phone: 813-817-7984, email: amanda.gonzalez@cenexel.com, contacts name: Craig Shapiro, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 26.0112, lon: -80.14949, hasResults: False
protocolSection identificationModule nctId: NCT06264986, orgStudyIdInfo id: 2023-09-02, briefTitle: The Effects of Ashwagandha (Withania Somnifera) Supplementation on Exercise Performance in Female Footballers, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-13, primaryCompletionDateStruct date: 2024-02-21, completionDateStruct date: 2024-02-21, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Blanca Roman-Viñas, MD, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the effects of short-term root extract ashwagandha supplementation on exercise performance in female footballers. The main question it aims to answer are:Will short-term supplementation of root extract ashwagandha improve muscle strength markers in female footballers? Will short-term supplementation of root extract ashwagandha improve perception of recovery following high-intensity exercise in female footballers?Participants will either supplement 600mg (5% withanolides) root extract ashwagandha or placebo once a day for 28 days. There will be three data points: baseline, 14 days and 28 days. Researchers will compare values of intervention against placebo to see if there is an effect on muscle strength or perception of recovery., conditionsModule conditions: Muscle Strength, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Double-blind, placebo-controlled, randomised trial, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Ashwagandha, interventions name: Placebo, outcomesModule primaryOutcomes measure: Increased lower body muscle strength, primaryOutcomes measure: Increased maximum voluntary muscle strength, primaryOutcomes measure: Increased upper body muscle strength and explosiveness, primaryOutcomes measure: Improved overall muscle strength, secondaryOutcomes measure: Improved perception of wellbeing, secondaryOutcomes measure: Improved perception of recovery, eligibilityModule sex: FEMALE, minimumAge: 17 Years, maximumAge: 40 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Club Esportiu Seagull, city: Badalona, state: Barcelona, zip: 08917, country: Spain, geoPoint lat: 41.45004, lon: 2.24741, hasResults: False
protocolSection identificationModule nctId: NCT06264947, orgStudyIdInfo id: CMUH112-REC2-141, briefTitle: Efficacy of Laser Acupuncture on Zanzhu (BL02) for Dry Age-related Macular Degeneration, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-26, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2024-11-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: China Medical University Hospital, class: OTHER, descriptionModule briefSummary: This study is to see if laser acupuncture is a better way to treat dry-AMD (Age-related Macular Degeneration) compared to sham laser acupuncture, in the aspect of visual acuity. Investigators planed to recruit participants who are diagnosed with dry-AMD, and not younger than 20 years old. Before the study, investigators will measure the participants' BCVA (Best Corrected Visual Acuity), and then practice laser acupuncture and sham-laser acupuncture on experiment group and control group respectively. After the 4-week study, investigators will measure the participants' BCVA again., conditionsModule conditions: Age-related Macular Degeneration, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: laser acupuncture, interventions name: sham laser acupuncture, outcomesModule primaryOutcomes measure: BCVA (Best Corrected Visual Acuity), eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: China Medical University Hospital, city: Taichung, zip: 404, country: Taiwan, geoPoint lat: 24.1469, lon: 120.6839, hasResults: False
protocolSection identificationModule nctId: NCT06264934, orgStudyIdInfo id: DiCECT, briefTitle: An Investigation Into Dielectric Assessment of Permittivity and Cancer in Human Using a Novel Electrical Capacitance Tomography Scanner, acronym: DiCECT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-25, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Zedsen Limited, class: INDUSTRY, collaborators name: Imperial College Healthcare NHS Trust, descriptionModule briefSummary: The goal of this observational study is to investigate the ability of a the Z-scanner to identify and differentiate cancer and benign lesions from healthy breast tissue based on permittivity. The main questions it aims to answer are:1. Determine the permittivity values of the Z-scanner associated with healthy, benign, and malignant tissue in human breasts.2. Determine the repeatability, reproducibility, inter-and intra-operator variability of the Z-scanner., conditionsModule conditions: Breast Cancer, conditions: Benign Breast Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Breast scan using the Z-scanner, interventions name: Breast scan using the Z-scanner, outcomesModule primaryOutcomes measure: Measurement of complex permittivity of breast tissue components, secondaryOutcomes measure: Permittivity target-to-background contrast ratios for targets of interest (e.g. malignant lesion, benign lesion), otherOutcomes measure: Repeatability of the Z-scanner, otherOutcomes measure: Reproducibility of the Z-scanner, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Imperial College Healthcare NHS Trust, status: RECRUITING, city: London, country: United Kingdom, contacts name: Lesley Honeyfield, role: CONTACT, contacts name: Adrian Lim, role: PRINCIPAL_INVESTIGATOR, contacts name: Deborah Cunningham, role: SUB_INVESTIGATOR, contacts name: Sylvie Flais, role: SUB_INVESTIGATOR, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06264908, orgStudyIdInfo id: 20240125-010-000, briefTitle: An Integrated Self Management Programme to Improve Outcomes in Patients With Hand Osteoarthritis, acronym: OASIS-H, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-12, completionDateStruct date: 2028-04, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Dr Iris Tang Yan Ki, class: OTHER, collaborators name: Hospital Authority, Hong Kong, descriptionModule briefSummary: The goal of this trial is to evaluate the efficacy of an integrated self-management programme in improving clinical outcomes in patients with hand osteoarthritis (OA).This is an open-labelled, randomized controlled trial with an objective to determine the efficacy of an integrated self-management programme versus routine clinical care for participants with symptomatic hand OA.Participants will be randomized into early intervention group and routine clinical care groups in a 1:1 ratio. Patients who randomized into early intervention group will receive 8 week integrated self-management programme delivered by occupational therapists and rheumatology nurse on hand OA management. Patients who randomized into routine clinical care group will receive usual clinical care for OA for 26 weeks and then receive an identical 8 weeks integrated self-management programme. The primary outcome is the improvement in pain at 26 weeks between the two groups., conditionsModule conditions: Hand Osteoarthritis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Patients will be randomized into early intervention and routine clinical care (control) group. Patients in control group will crossover to receive the intervention at week 26., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Integrated self-management programme, outcomesModule primaryOutcomes measure: Change in Pain visual analogue scale (VAS), secondaryOutcomes measure: Change in pain Visual Analogue Scale (VAS), secondaryOutcomes measure: Change in Functional index hand osteoarthritis (FIHOA), secondaryOutcomes measure: Change in Quick Disabilities of the Arm, Shoulder, and Hand (DASH) score, secondaryOutcomes measure: Change in Australian/Canadian Hand Osteoarthritis Index (AUSCAN) 3.1, secondaryOutcomes measure: Change in Short-form 36 items health survey, secondaryOutcomes measure: Change in hand grip strength, secondaryOutcomes measure: Change in hand dexterity measurement, secondaryOutcomes measure: Radiographic changes, otherOutcomes measure: Adverse events, otherOutcomes measure: Use of rescue pain medication, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06264869, orgStudyIdInfo id: 141123, briefTitle: Interdental Guided Creeping Technique, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2024-11, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: October 6 University, class: OTHER, descriptionModule briefSummary: The aim of this randomized clinical trial is to treat interdental papillary deficiency with minimally invasive interdental guided creeping technique (IGCT) comparing collagen membrane versus connective tissue graft., conditionsModule conditions: Interdental Papilla Recession, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Interdental guided creeping technique (IGCT) and connective tissue graft (CTG), interventions name: Interdental guided creeping technique (IGCT) and collagen membrane (CM), outcomesModule primaryOutcomes measure: Black triangle height, secondaryOutcomes measure: Percentage of interdental papillary fill, secondaryOutcomes measure: Papillary gain, black triangle reduction, secondaryOutcomes measure: Papillary height, attached gingiva width, secondaryOutcomes measure: Pocket depth, clinical attachment level, keratinized tissue thickness, secondaryOutcomes measure: Plaque index, secondaryOutcomes measure: Gingival index, secondaryOutcomes measure: Duration of surgery, secondaryOutcomes measure: Patient Reported Outcome, secondaryOutcomes measure: Patient Reported Outcome, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06264856, orgStudyIdInfo id: 202210096RIND, briefTitle: Bronchoscopy for Thoracic Trauma Patients, statusModule overallStatus: SUSPENDED, startDateStruct date: 2024-12-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: National Taiwan University Hospital, class: OTHER, descriptionModule briefSummary: The study aims to evaluate the effectiveness of bronchoscopic sputum suction in patients with severe thoracic illness-induced respiratory failure. The study will compare the outcomes of patients who receive bronchoscopic sputum suction versus blind negative pressure aspiration for sputum removal. The study will measure baseline data, postoperative blood gas conditions, and clinical parameters, such as time of invasive ventilation, total time of ventilation, hospital stay, weaning success rate, reintubation rate, ventilator-associated pneumonia incidence, and fatality rate. The study aims to determine whether bronchoscopy-assisted sputum removal is superior to blind negative pressure aspiration in improving patient outcomes., conditionsModule conditions: Chest Trauma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: bronchoscopic sputum suction, interventions name: negative pressure aspiration suction, outcomesModule primaryOutcomes measure: Rate of pneumonia, secondaryOutcomes measure: Intensive Care Unit admission interval, secondaryOutcomes measure: admission interval, secondaryOutcomes measure: tracheostomy rate, secondaryOutcomes measure: intubation rate, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Traumatology, National Taiwain University Hospital, city: Taipei, zip: 10002, country: Taiwan, geoPoint lat: 25.04776, lon: 121.53185, locations facility: NTUH Hsin-Chu Branch; NTUH Yun-Lin Branch, city: Taipei, zip: 100; 300; 640; 280, country: Taiwan, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06264843, orgStudyIdInfo id: 724, briefTitle: Peripheral Bypass Trial for Completion Control, acronym: PATENT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2027-12, completionDateStruct date: 2027-12, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Medistim ASA, class: INDUSTRY, descriptionModule briefSummary: The goal of the study is to identify and validate flow measurement and ultrasound images in patients undergoing vein bypass surgery below-knee and above ankle, conditionsModule conditions: Chronic Limb-Threatening Ischemia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 450, type: ESTIMATED, armsInterventionsModule interventions name: Medistim MiraQ system with TTFM and L15 HFUS probes, outcomesModule primaryOutcomes measure: Primary graft patency rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False